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ABSTRACT 
Nebivolol1chemically [1-(6-fluorochroman-2-yl)-{[2-(6-fluorochroman-2-yl)-2-hydroxy-
ethyl] amino} ethanol)] is a long acting cardio selective beta-blocker currently used for the 
treatment of hypertension. A sensitive and precise RP-HPLC method has been developed and 
validated for the determination of Nebivolol in dosage forms. The drug was chromatographed on 
a C-18 column using a mixture of water and Methanol in the ratio (40:60) as mobile phase at a 
flow rate of 1.0 ml/min. Chlorzoxazone was used as an internal standard and detection was done 
at 282 nm. Linearity range is found to be 5-100 µg/ml with a correlation coefficient 0.9999 .The 
mean recoveries obtained for Nebivolol range from 99.6-100.8%. Due to its simplicity, 
rapidness, high precision and accuracy the proposed method may be used for determining 
Nebivolol in bulk and dosage forms. 
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INTRODUCTION 
 
Nebivolol1 chemically [1-(6-fluorochroman-2-yl)-{[2-(6-fluorochroman-2-yl)-2-hydroxy-
ethyl] amino} ethanol)] is a long acting cardio selective beta blocker currently used for the 
treatment of hypertension. A survey of literature revealed that very few methods for the 
separation and estimation of Nebivolol have been reported. Simultaneous determination of fixed 
dose combination of Nebivolol and valsartan in human plasma by liquid chromatographic-
tandem mass spectrometry and its application to pharmacokinetic study have been reported2, 
Rapid quantification of   Nebivolol in human plasma by liquid chromatography coupled with 
electro spray ionization tandem mass spectrometry 3.and a stability–indicating column high-
performance liquid chromatographic assay method for determination of Nebivolol in tablet 
formulation4have been reported. The authors now propose a precise and accurate HPLC method 
for the determination of Nebivolol in this communication. 
 
EXPERIMENTAL PROCEDURE 
 Instrumentation:  
 
An isocratic HPLC system Shimadzu LC10AT VP series HPLC pumps, and SPD 10A 
VP UV-Visible absorbance detector, Hamilton injecting syringe and Shimadzu CLASS-VP 
Version 6.12 SP1software,  Hypersil ODS C-18 (250 x 4.6 mm, packed with 5 micron) column 
were used for the separation. 
 
Drugs and Chemicals: 
 
 Pure samples of Nebivolol and Chlorzoxazone  (internal standard) were gifted by Cadila 
Pharmaceuticals Pvt.ltd (Ahmedabad, India) and Elder pharmaceuticals  Limited (Mumbai, 
India) respectively. And Nebistar tablets (Lupin,  pharma) containing 2.5 mg  5 mg, and 10mg of 
Nebivolol  were purchased from the local market. Purified water was prepared using a Millipore 
Milli-Q (HPLC grade) water purification system. Acetonitrile used as HPLC grade.  
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Chromatographic conditions: 
 
  The mobile phase used in this study was a mixture of water and Methanol in the ratio of 
40:60 v/v. The mobile phase was filtered before use through a 0.45 µ membrane and degassed 
for 15 min. The mobile phase was pumped from the solvent reservoir to the column at a flow rate 
of 1.0 ml/min. The column temperature was maintained at 25±10C.The eluents were monitored at 
282 nm. 
 
Procedure:  
 
Stock solution of the drug and internal standard were prepared by dissolving 10mg of 
Nebivolol and 10 mg of internal standard (chlorzoxazone) separately in 10 ml volumetric flasks 
to get 1mg/ml solution and sonicated for about 10 min to ensure complete solubility of drug. 
Subsequent dilutions of this solution ranging from 5-100 µg/ml were made in 10ml volumetric 
flasks after addition of 5ml Chlorzoxazone (5µg/ml) as internal standard to each dilution. Before 
injection of the drug solutions, the column was equilibrated at least for 30 min with the mobile 
phase flowing through the system.20µl of each solution was injected in to the HPLC system to 
obtain the chromatogram. The area under the peaks of the drug and the internal standard were 
noted. Using these values the mean peak area ratio of the drug to that of internal standard for 
each dilution was calculated. Regression of the drug concentration over these ratios was 
computed. Calibration curve was constructed by plotting mean peak area against the 
corresponding drug concentrations. Model chromatogram was shown in fig-1. 
 
Estimation of Nebivolol in Tablet dosage forms:  
 
Ten tablets were weighed to get the average weight and pulverized and the powder 
equivalent to 10mg of Nebivolol was extracted with methanol and sonicated for about 15 min   
and made-up the volume to 10 ml to get a stock solution of 1 mg/ml.  This solution was filtered 
through a 0.45 µ membrane filter.  This solution was further diluted stepwise with mobile phase 
and spiked with required amount of internal standard. These solutions were injected into the 
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column .The mean peak area ratio of the drug to the internal standard was calculated. The drug 
content in the tablets was quantified using the regression equation. The results are given in table-
3. 
 
METHOD VALIDATION 
 
Linearity:  
 
The standard curve was obtained in the concentration range of 5-100 µg/mL. The 
linearity of the method was evaluated by regression analysis using the least squares method. 
 
Precision:  
 
The precision of the assay was determined in terms of repeatability and intra and inter-
day variations in the peak areas for a set of drug solutions on three different days. The intra and 
inter-day variation in the peak area ratio of the drug solution to that of internal standard was 
calculated in terms of %R.S.D. 
 
Accuracy:  
 
To determine the accuracy of the proposed method, recovery studies were carried out by 
adding different amounts of bulk sample Nebivolol and internal standard to the pre-analyzed 
formulation. 
 
System suitability:  
 
 System suitability studies were carried out as specified in U.S.P. These 
parameters include column efficiency (N), resolution (R), capacity factor (K’), Selectivity factor 
(α) and Peak asymmetry factor (AS). 
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RESULTS AND DISCUSSION 
 
To achieve sharp peaks with good resolution under isocratic conditions several mobile 
phase compositions were tried. Peak symmetry was obtained with mobile phase consisting of 
Water: Methanol (40:60). Quantification was achieved with UV detection at 282nm.Under the 
above mentioned chromatographic conditions the retention time obtained for Nebivolol and 
internal standard were 3.150and 4.125 min. A model chromatogram is shown in fig-1. The linear 
regression data showed a good linear relationship over a concentration range 5-100µg/ml The 
regression curve was constructed by linear regression fitting into mathematical expression 
Y=0.0407+0.0174X(r=0.9999) where Y is the peak area ratio and X is the concentration. These 
values are given in (Table-1).The intra-day and inter-day precision were determined by 
analyzing Nebivolol solutions containing 20 and 80µg/ml by the proposed method .A low 
coefficient of variation was observed. This shows that the present HPLC method is highly 
precise. 
Accuracy and recovery studies were carried out using standard addition method All 
solutions were prepared and analyzed in triplicate .There was a high recovery 100.8±1.38 of 
Nebivolol indicating that the proposed methods is highly accurate. %recovery values were given 
in (Table-2). The drug content in tablets was quantified using the proposed analytical method. 
Results were shown in table-3.The system suitability parameters are theoretical plates(n) -
1600,Tailing factor (T)-1.33, Resolution (R)-0.98, also revealed that the values are with in the 
specified limits. 
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Table-1 
 
 CALIBRATION OF THE HPLC METHOD FOR THE ESTIMATION OF NEBIVOLOL 
  
Concentration (µg/ml) Peak area ratio 
5 0.245 
10 0.410 
20 0.8193 
30 1.2389 
40 1.6437 
50 2.0626 
80 3.275 
100 4.093 
 
 
 
             
CALIBRATION CURVE OF NEBIVOLOL
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Fig-1 HPLC Chromatogram of Nebivolol 
 
        Fig-2   UV-Spectra of nebivolol 
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TABLE- 2 
ACCURACY STUDIES 
 
Amount of drug added (mg) 
N=3 
Amount found (Mean±sd) 
N=3 
%recovery(Mean± sd) 
N=3 
2.5 2.49±0.02 100.08±1.02 
5 4.98±0.06 99.6±1.19 
7.5 7.56±0.10 100.8±1.38 
 
 
TABLE-3 
AMOUNT OF NEBIVOLOL IN DOSAGE FORMS BY THE PROPOSED HPLC METHOD 
 
Formulation Labeled Claim(mg) Amount found 
mg±sd 
%recovery(±sd) 
Brand I 
Brand II 
5.0 
5.0 
5.068±0.02 
5.077±0.01 
101.36±0.69 
101.54±0.16 
 
CONCLUSION: 
 
The proposed method was found to be simple, precise, accurate and rapid for 
determination of Nebivolol in pure state and its dosage forms. The mobile phase is simple to 
prepare and economical. The sample recoveries in all formulations were in good agreement with 
their respective label claims and they suggested non- interference of formulation excipients in 
the estimation. Hence, this method   can be   easily and   conveniently adopted for routine 
analysis of nebivolol in pure form and its dosage form.  
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